Invivyd Inc. (IVVD) - Total Assets
Based on the latest financial reports, Invivyd Inc. (IVVD) holds total assets worth $241.74 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Invivyd Inc. - Total Assets Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s total assets have evolved over time, based on quarterly financial data. Also see market cap of Invivyd Inc. for the company's overall valuation and market capitalisation.
Invivyd Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Invivyd Inc.'s total assets of $241.74 Million consist of 89.4% current assets and 10.6% non-current assets. Review Invivyd Inc. (IVVD) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.9% |
| Accounts Receivable | $14.60 Million | 5.3% |
| Inventory | $25.50 Million | 9.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Invivyd Inc. (IVVD) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Invivyd Inc.'s current assets represent 89.4% of total assets in 2025, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 81.9% of total assets in 2025, down from 98.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 9.2% of total assets.
Invivyd Inc. Competitors by Total Assets
Key competitors of Invivyd Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Invivyd Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.47 | 1.53 | 10.45 |
| Quick Ratio | 5.67 | 1.52 | 10.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $173.26 Million | $26.23 Million | $358.16 Million |
Invivyd Inc. - Advanced Valuation Insights
This section examines the relationship between Invivyd Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.98 |
| Latest Market Cap to Assets Ratio | 0.75 |
| Asset Growth Rate (YoY) | 113.8% |
| Total Assets | $276.88 Million |
| Market Capitalization | $207.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values Invivyd Inc.'s assets below their book value (0.75x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Invivyd Inc.'s assets grew by 113.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Invivyd Inc. (2020–2025)
The table below shows the annual total assets of Invivyd Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $276.88 Million | +113.78% |
| 2024-12-31 | $129.51 Million | -43.49% |
| 2023-12-31 | $229.18 Million | -40.19% |
| 2022-12-31 | $383.17 Million | -38.21% |
| 2021-12-31 | $620.09 Million | +428.27% |
| 2020-12-31 | $117.38 Million | -- |
About Invivyd Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through in… Read more